FHTXFoghorn Therapeutics Inc.

$330M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+23.0% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$27M-386.6% margin

Net Income

-$23M-333.6% margin

EPS (Diluted)

$-0.45

QoQ Revenue Growth

+36.4%

Cash Flow

Operating Cash Flow

-$26M

Free Cash Flow

-$26M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$329M

Total Liabilities

$343M

Stockholders' Equity

-$14M

Cash & Equivalents

$139M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$6M	+23.0%
Gross Profit	$7M	-$24M	+129.1%
Operating Income	-$27M	-$32M	+16.9%
Net Income	-$23M	-$29M	+22.1%

FHTX Q2 2024 Earnings — Foghorn Therapeutics Inc. Revenue & Financial Results | Market Cap Arena